New facets of antifungal therapy

Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis

(2016) A. Kyvernitakis et al.   CLINICAL MICROBIOLOGY AND INFECTION

Antifungal Agents

(2016) Jeniel E. Nett et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Utility of voriconazole therapeutic drug monitoring: a meta-analysis

(2016) Me-Linh Luong et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections

(2016) Aaron N. Pham et al.   MYCOSES

Combinatorial strategies for combating invasive fungal infections

(2016) Michaela Spitzer et al.   Virulence

Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients—an evidence-based approach

(2015) Meinolf Karthaus et al.   ANNALS OF HEMATOLOGY

Combination Antifungal Therapy for Invasive Aspergillosis

(2015) Kieren A. Marr et al.   ANNALS OF INTERNAL MEDICINE

Isavuconazole

(2015) Natasha N. Pettit et al.   ANNALS OF PHARMACOTHERAPY

Mechanisms of echinocandin antifungal drug resistance

(2015) David S. Perlin   Annals of the New York Academy of Sciences

Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension

(2015) Urshila Durani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis

(2015) E. P. Garvey et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies

(2015) Aaron Cumpston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates

(2015) Frédéric Lamoth et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent

(2015) Marisa H. Miceli et al.   CLINICAL INFECTIOUS DISEASES

Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values

(2015) M.A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Posaconazole: A Review of the Gastro-Resistant Tablet and Intravenous Solution in Invasive Fungal Infections

(2015) Kate McKeage   DRUGS

The ‘cephalosporin era’ of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections

(2015) Maria N Chitasombat et al.   EXPERT OPINION ON PHARMACOTHERAPY

Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update

(2015) Zoi-Dorothea Pana et al.   EXPERT OPINION ON PHARMACOTHERAPY

Impact of special patient populations on the pharmacokinetics of echinocandins

(2015) Eline W Muilwijk et al.   Expert Review of Anti-Infective Therapy

Azole antifungals: 35 years of invasive fungal infection management

(2015) David Allen et al.   Expert Review of Anti-Infective Therapy

Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs

(2015) Damian J. Krysan   FUNGAL GENETICS AND BIOLOGY

Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies

(2015) Issam I. Raad et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

(2015) Oliver A. Cornely et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Nontoxic antimicrobials that evade drug resistance

(2015) Stephen A Davis et al.   Nature Chemical Biology

Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms

(2015) Diarmaid Hughes et al.   NATURE REVIEWS GENETICS

Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent

(2015) Jeffrey M. Rybak et al.   PHARMACOTHERAPY

Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease

(2015) Kim C. M. van der Elst et al.   THERAPEUTIC DRUG MONITORING

Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial

(2015) D. Neofytos et al.   Transplant Infectious Disease

Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease

(2014) Johan Maertens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using anIn VivoMurine Invasive Candidiasis Model

(2014) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme

(2014) A. G. S. Warrilow et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Update on Epidemiology of and Preventive Strategies for Invasive Fungal Infections in Cancer Patients

(2014) J. R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

(2014) Maiken C. Arendrup et al.   DRUG RESISTANCE UPDATES

Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments

(2014) Daniel Michał Kamiński   EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS

Drug safety assessment of oral formulations of ketoconazole

(2014) Aditya K Gupta et al.   Expert Opinion On Drug Safety

Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases

(2014) Seyedmojtaba Seyedmousavi et al.   Expert Review of Anti-Infective Therapy

Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects

(2014) Nasrullah A. Undre et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Liver injury associated with ketoconazole: Review of the published evidence

(2014) H. Karl Greenblatt et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Emerging drugs and vaccines for Candidemia

(2014) Brad Moriyama et al.   MYCOSES

Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches

(2014) T. Roemer et al.   Cold Spring Harbor Perspectives in Medicine

Voriconazole Therapeutic Drug Monitoring

(2014) Z. Hoy et al.   Journal of the Pediatric Infectious Diseases Society

Interactions Between Anti-Infective Agents and Immunosuppressants in Solid Organ Transplantation

(2013) J. Trofe-Clark et al.   AMERICAN JOURNAL OF TRANSPLANTATION

In VitroStudy of Sequential Fluconazole and Caspofungin Treatment against Candida albicans Biofilms

(2013) Semanti Sarkar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Enfumafungin Derivative MK-3118 Shows IncreasedIn VitroPotency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates

(2013) Cristina Jiménez-Ortigosa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of Pediatric Refractory Coccidioidomycosis With Combination Voriconazole and Caspofungin: A Retrospective Case Series

(2013) E. R. Levy et al.   CLINICAL INFECTIOUS DISEASES

Optimizing antifungal choice and administration

(2013) David Andes   CURRENT MEDICAL RESEARCH AND OPINION

Azole resistance in Aspergillus fumigatus

(2013) Edith Vermeulen et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex

(2013) Rolin L. Wade et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity

(2013) Richard J. Hamill   DRUGS

Cardiac toxicity of some echinocandin antifungals

(2013) Kayla R Stover et al.   Expert Opinion On Drug Safety

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

(2013) H. R. Ashbee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

A severe case of haemodynamic instability during anidulafungin administration

(2013) M. Fink et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

C2′-OH of Amphotericin B Plays an Important Role in Binding the Primary Sterol of Human Cells but Not Yeast Cells

(2013) Brandon C. Wilcock et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Efficiently Killing a Sugar-Coated Yeast

(2013) John R. Perfect   NEW ENGLAND JOURNAL OF MEDICINE

Combination Antifungal Therapy for Cryptococcal Meningitis

(2013) Jeremy N. Day et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration

(2012) Michael J. Dolton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring

(2012) Michael J. Dolton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial

(2012) Wan Beom Park et al.   CLINICAL INFECTIOUS DISEASES

Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials

(2012) D. R. Andes et al.   CLINICAL INFECTIOUS DISEASES

Mucormycosis treated with posaconazole: review of 96 case reports

(2012) Joerg J. Vehreschild et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections

(2012) Joanne Livermore et al.   Expert Opinion on Drug Metabolism & Toxicology

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers

(2012) G. Krishna et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Theo Vos et al.   LANCET

Incidence and outcome of earlyCandidaperitonitis after liver and pancreas transplantation

(2012) Michele Bartoletti et al.   MYCOSES

Amphotericin primarily kills yeast by simply binding ergosterol

(2012) K. C. Gray et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antifungal Drug Resistance: Mechanisms, Epidemiology, and Consequences for Treatment

(2011) Michael A. Pfaller   AMERICAN JOURNAL OF MEDICINE

Discovery of a Novel Class of Orally Active Antifungal β-1,3-d-Glucan Synthase Inhibitors

(2011) Scott S. Walker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Fks Hot Spot for Acquired Echinocandin Resistance inSaccharomyces cerevisiaeand Its Contribution to Intrinsic Resistance ofScedosporiumSpecies

(2011) Michael E. Johnson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin

(2011) Takao Ogawa et al.   AURIS NASUS LARYNX

Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis

(2011) A. Loyse et al.   CLINICAL INFECTIOUS DISEASES

Triazole Antifungal Agents in Invasive Fungal Infections

(2011) Cornelia Lass-Flörl   DRUGS

Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations

(2011) Stuart K Pitman et al.   EXPERT OPINION ON EMERGING DRUGS

Current Concepts in Antifungal Pharmacology

(2011) Russell E. Lewis   MAYO CLINIC PROCEEDINGS

Novel, unifying mechanism for amphotericin B and other polyenedrugs: electron affinity, radicals, electron transfer, autoxidation, toxicity, and antifungal action.

(2011) Peter Kovacic et al.   MedChemComm

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update

(2010) J Maertens et al.   BONE MARROW TRANSPLANTATION

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Lack of Pharmacokinetic Drug Interaction Between Oral Posaconazole and Caspofungin or Micafungin

(2010) Gopal Krishna et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole

(2010) George R. Thompson et al.   MYCOPATHOLOGIA

Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients

(2010) Heinrich Lellek et al.   MYCOSES

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

New generation azole antifungals in clinical investigation

(2009) Corrado Girmenia   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Antifungal drug resistance mechanisms

(2009) Javier Pemán et al.   Expert Review of Anti-Infective Therapy

Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

(2008) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America

(2008) Stanley W. Chapman et al.   CLINICAL INFECTIOUS DISEASES

Combination Polyene‐Caspofungin Treatment of Rhino‐Orbital‐Cerebral Mucormycosis

(2008) Caitlin Reed et al.   CLINICAL INFECTIOUS DISEASES

The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals

(2008) Yasmine Nivoix et al.   CLINICAL PHARMACOKINETICS

Resistance to Antifungal Agents: Mechanisms and Clinical Impact

(2007) Z. A. Kanafani et al.   CLINICAL INFECTIOUS DISEASES

Salvage therapy for invasive aspergillosis

(2007) D. H. Dockrell   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY